Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCP-001 dendritic cell vaccine in AML patients in remission with persistent MRD
2017-003426-32Phase 2Completed
- Sponsor
- DCprime
- Start
- Sep 2017
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of vididencel in acute myeloid leukemia (AML) (2 arms), sponsored by DCprime. Started Sep 2017; status: completed.
02
Drugs
vididencel
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2017-003426-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003426-32.